

OMB APPROVAL	
OMB Number:	3235-0287
Estimated average burden hours per response:	0.5

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* <u>Maetzel Andreas</u>			2. Issuer Name and Ticker or Trading Symbol <u>KalVista Pharmaceuticals, Inc. [KALV]</u>			5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director _____ 10% Owner _____ Officer (give title below) _____ Other (specify below) _____ X <u>Senior Vice President, Medical</u>		
(Last)	(First)	(Middle)	3. Date of Earliest Transaction (Month/Day/Year) <u>04/27/2021</u>			6. Individual or Joint/Group Filing (Check Applicable Line) X Form filed by One Reporting Person Form filed by More than One Reporting Person		
C/O KALVISTA PHARMACEUTICALS, INC. 55 CAMBRIDGE PARKWAY, SUITE 901E			4. If Amendment, Date of Original Filed (Month/Day/Year)					
(Street) <u>CAMBRIDGE MA 02142</u>								
(City) (State) (Zip)								

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price			
Common Stock	04/27/2021		M		11,017	A	\$7.91	11,017	D	
Common Stock	04/27/2021		S		11,017	D	\$25.7931	0	D	
Common Stock	04/28/2021		M		36,127	A	\$7.91	36,127	D	
Common Stock	04/28/2021		S		10,620	D	\$25.5	25,507	D	
Common Stock	04/28/2021		S		15,000	D	\$25.2522	10,507	D	
Common Stock	04/28/2021		S		10,000	D	\$25.5387	507	D	
Common Stock	04/28/2021		S		507	D	\$25.65	0	D	
Common Stock	04/29/2021		M		12,856	A	\$7.91	12,856	D	
Common Stock	04/29/2021		M		14,662	A	\$8.21	27,518	D	
Common Stock	04/29/2021		M		13,368	A	\$16.08	40,886	D	
Common Stock	04/29/2021		S		40,886	D	\$25.0352	0	D	

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)	8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)	
				Code	V	(A)	(D)	Date Exercisable	Expiration Date						Title
Employee Stock Option (right to buy)	\$7.91	04/27/2021		M		11,017		(1)	03/07/2027	Common Stock	11,017	\$0.00	48,983	D	
Employee Stock Option (right to buy)	\$7.91	04/28/2021		M		36,127		(1)	03/07/2027	Common Stock	36,127	\$0.00	12,856	D	
Employee Stock Option (right to buy)	\$7.91	04/29/2021		M		12,856		(1)	03/07/2027	Common Stock	12,856	\$0.00	0	D	
Employee Stock Option (right to buy)	\$8.21	04/29/2021		M		14,662		(2)	06/03/2028	Common Stock	14,662	\$0.00	6,038	D	
Employee Stock Option (right to buy)	\$16.08	04/29/2021		M		13,368		(3)	09/17/2028	Common Stock	13,368	\$0.00	7,332	D	

Explanation of Responses:

1. The option is fully vested.
2. The option vests over a 4-year period: 1/48th on July 4, 2018, after which 1/48th of the total shares vest monthly, subject to continued service through each vesting date.
3. The option vests over a 4-year period: 1/48th on October 18, 2018, after which 1/48th of the total shares vest monthly, subject to continued service through each vesting date.

Remarks:

/s/ Benjamin L. Palleiko,
Attorney-in-Fact

04/29/2021

** Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.